GRONINGEN INTERNATIONAL STUDY ON SENTINEL NODES IN VULVAR CANCER III, A PROSPECTIVE PHASE II TREATMENT TRIAL

S
Sharon E. Robertson

Primary Investigator

Enrolling By Invitation
18-100 years
Female
Phase 2
2 Locations

Brief description of study

What is the purpose of this study?
The primary objective of this study is to investigate the safety of replacing inguinofemoral lymphadenectomy by chemoradiation in early stage vulvar cancer patients with a macrometastasis (>2mm) and/or extracapsular extension in the SN. The secondary objective is to evaluate the short and long-term morbidity associated with the SN procedure and chemoradiation.
 
THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. 
 
Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office 
Phone: (317) 278-5632

Detailed description of study

What will happen during the study?
Participants will be treated with chemoradiation, in a total dose of 56Gy to the involved site, combined with weekly cisplatin 40mg/m2 for 5 weeks.
 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases
  • Age: Between 18 Years - 100 Years
  • Gender: Female

Inclusion Criteria:

  •     Histological confirmed primary SCC of the vulva
  •    T1 tumor, not encroaching urethra/vagina/anus
  •    Depth of invasion > 1mm
  •    Tumor diameter < 4cm
  •    Unifocal tumor
  •    No enlarged (>1.5cm) or suspicious inguinofemoral lymph nodes at imaging (CT/MRI/ultrasound)
  •    Possibility to obtain informed consent
  •    Metastatic sentinel lymph node; size of metastasis > 2mm and / or extracapsular extension, or
  •    Metastatic sentinel lymph node: more than 1 SN with metastasis ≤ 2mm
  •    Patients are able to understand requirements of study, provide written informed consent and comply with the study and follow-up procedures
  •    Adequate bone marrow, renal and liver function:
  •        Absolute neutrophil count ≥ 1.5 x 109 /L
  •        Platelet count ≥ 100 x 109 /L
  •        Creatinine clearance ≥ 40 ml/min measured by the Cockroft Gault formula
  •        Total bilirubin < 1.25 x ULN Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN
  •    Performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale (Appendix A)
  •    Age 18 years or older
  •    Life expectancy of ≥ 12 weeks
  •    Written informed consent


Exclusion Criteria:

  •     Inoperable tumors and tumors > 4cm
  •    Multifocal tumors
  •    Tumors with other pathology than squamous cell carcinoma
  •    Patients with enlarged / suspicious lymph nodes which are proven metastatic after fine needle aspiration cytology
  •    No other carcinomas, other than basal cell carcinomas, within last 5 years
  •    History of pelvic radiotherapy
  •    History of any infection requiring hospitalization or antibiotics within 2 weeks before enrollment
  •    Pregnant female or nursing mother
  •    Desire to become pregnant
  •    Known brain or spinal cord metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids
  •    Unstable angina, myocardial infarction, cerebrovascular accident, > Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure (see Appendix B) within 6 months before enrollment

Updated on 05 Nov 2024. Study ID: CTO-NRG-GY024
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center